| Abstrakt: |
A recent study conducted by researchers at the University of British Columbia explores the potential of a novel type of immunotherapy for cancer treatment. The study focuses on Type 2 innate lymphoid cells (ILC2s) and interleukin-33 (IL-33), which have been found to enhance immune responses and inhibit tumor growth. The researchers discovered that adoptively transferring ILC2s into tumor-bearing mice resulted in a significant reduction in tumor growth and an increase in tumor-infiltrating immune cells. The study suggests that ILC2 cell-based immunotherapy may be more effective than other approaches, such as CAR T-cell therapy, in targeting and eliminating tumors. [Extracted from the article] |
